Marvel Biosciences plans to launch an early clinical trial in the coming months to test MB-204, its lead therapy candidate for fragile X syndrome and other neurological conditions, in healthy volunteers. The Phase 1 trial will be possible due to funding and expert guidance from 5 Horizons…
The FRAXA Research Foundation will provide financial support to the principal investigators involved in a planned Phase 2b clinical trial of SPG601, an experimental oral therapy being developed for people with fragile X syndrome. “We are thrilled to have the support of FRAXA as part of our journey…
Fragile X syndrome is a genetic condition associated with cognitive impairment, learning and behavioral challenges, and several physical features. Learn more about the disease here.
Fragile X is caused by mutations in the fragile X mental retardation 1 (FMR1) gene, located in the X chromosome. Learn more about what causes the disease here.
Symptoms differ in severity and occurrence among patients. Life expectancy for fragile X patients is generally normal. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
